secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001387131-23-000543
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports preliminary 2022 cash $120.2M; burn $98.1M; new $12.5M buyback
----------------------------------------------------------------------------

- Preliminary cash $120.2M at Dec 31, 2022; shares outstanding 76.5M then, 60.9M as of Jan 24, 2023 after repurchases.
- Net cash used in operations $98.1M in FY2022 vs $75.6M in FY2021; capex $48.1M vs $35.3M.
- Equity proceeds from stock sales $94.5M in 2022 vs $212.4M in 2021.
- Since Jan 1, 2023 repurchased 15.7M shares at $0.44-$1.38 under existing $12.5M program.
- Board approved new $12.5M share repurchase program funded with available cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123000543/0001387131-23-000543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123000543/tnxp_8k-012523.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-000543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer